Zymeworks gets Fast Track
Zymeworks’ FRα‑targeting ADC ZW191 received FDA Fast Track designation for platinum‑resistant ovarian cancer, a development likely to drive demand for companion biomarker testing from effusions and small biopsies. Therapeutic advances like this typically increase pressure on labs to deliver reliable molecular and protein assays from limited cytology material. (biospace.com, rttnews.com)
Phase 1 of the global ZW191 study is registered as NCT06555744 and was last updated on ClinicalTrials.gov on March 6, 2026; the trial lists dose‑finding and safety/tolerability as primary objectives in advanced solid tumors including ovarian cancer. (clinicaltrials.gov) ZW191 is described in company and conference materials as a fully humanized IgG1 antibody‑drug conjugate linked to a novel topoisomerase‑I inhibitor payload, ZD06519, engineered for FRα‑targeted internalization. (esmoopen.com) Zymeworks has already reported initial Phase 1 clinical data and has scheduled further clinical updates with an oral presentation of ZW191 data at an upcoming scientific meeting on April 21, 2026. (biospace.com) Published estimates used in recent company reporting put FRα expression at roughly 75% in high‑grade serous ovarian carcinoma, with other tumor‑type figures cited around >50% in endometrial cancers and ~70% in lung adenocarcinomas — numbers that shape anticipated testing volumes for FRα assays. (rttnews.com) An FDA‑cleared IHC companion diagnostic for FRα (VENTANA FOLR1 [FOLR1‑2.1] RxDx) exists with the approved scoring algorithm requiring ≧75% of viable tumor cells showing moderate/strong membrane staining for positivity in epithelial ovarian cancer. (fda.gov) Peer‑reviewed work has demonstrated that FRα protein can be detected by IHC on serous effusion cell blocks and that optimized cell‑block techniques (including agarose/frozen‑embedded methods) improve antigen preservation for immunocytochemistry on limited cytology material. (onlinelibrary.wiley.com) Commercial and lab‑partner programs report that roughly one in three patients with platinum‑resistant ovarian cancer will test positive for therapeutically actionable FRα by current companion testing algorithms, which provides an operational positivity‑rate benchmark for cytology laboratories validating FRα IHC on small biopsies and effusion cell blocks. (myriad.com) FDA Fast Track program guidance notes the designation’s procedural benefits — notably more frequent sponsor‑FDA communications and eligibility for rolling review of regulatory submissions — mechanisms that can compress development timelines and influence the urgency of companion‑diagnostic deployment in clinical labs. (fda.gov)
